Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indacaterol versus placebo with tiotropium active control in moderate COPD
2009-013686-26Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of indacaterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Novartis. Primary endpoint: Peak inspiratory capacity after 21 days of treatment. Started Sep 2009; status: completed.
02
Drugs
indacaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2009-013686-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013686-26.